Compare Abeona Therapeutics Inc (ABEO) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Otis Worldwide Corp — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Otis Worldwide Corp trades at $72.37 (market cap $28.18B). The key difference: Otis Worldwide Corp is far larger — about 75.5× Abeona Therapeutics Inc's market cap, and Otis Worldwide Corp pays a 2.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | OTIS | |
|---|---|---|
Market Cap | $373.32M | $28.18B |
Sector | Health | Industrials |
52-Week High | $7.23 | $101.07 |
52-Week Low | $4.17 | $69.34 |
Enterprise Value | $228.22M | $35.56B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
OTIS trades at $73.43, up 0.4% today, with a bullish technical signal and strong support at $72. The company reported $14.43B in 2025 revenue, a 10.11% net income margin, and a P/E of 19.55. Recent news highlights elevator modernization projects and a 5% dividend increase to $0.44 per share. Earnings have been mixed, with a Q1 2026 miss but service segment growth.
The stock offers a 28% upside to the $94 consensus price target, supported by buybacks and dividend growth, but faces risks from high debt and margin pressure. Analyst sentiment is mixed with 38% buy ratings. Execution on service growth and cost management is critical for re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
